1. Белоголовых Л.А., Дубиков А.И., Медведь Е.Э. Активность нитрооксидсинтаз на разных стадиях развития адъювантного артрита. Бюл. экспер. биол. и мед. 2007; 143 (5): 576–9.
2. Дубиков А.И., Белоголовых Л.А., Медведь Е.Э. и др. Влияние селективных и неселективных ингибиторов циклооксигеназ на нитрооксидсинтазную активность хряща и синовии при аутоиммунном артрите. Человек и лекарство. XI Российский национальный конгресс. Тез. докл. М., 2004; 783.
3. Насонов Е.Л. Нестероидные противовоспалительные препараты (перспективы применения в медицине). М.: Анко, 2000.
4. Применение   нестероидных   противовоспалительных   препаратов. Клинические рекомендации. М.: Алмаз, 2006.
5. Abramson SB. Nitric oxide in inflammation and pain associated with osteoarthritis. Arthritis Res Ther 2008; 10 (Suppl. 2): 2.
6. Baron JA, Sandler RS, Bresalier RS et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 2008; 6736: 61490–7.
7. Bertin P, Lapique F, Payan E et al. Sodium naproxen: concentration and effect on inflammatory response mediators in human rheumatoid synovial fluid. Eur J Clin Pharmacol 1994; 46: 3–7.
8. Bradley JD, Rudy AC, Katz BP et al. Correlation of serum concentrations of ibuprofen stereoisomers with clinical response in the treatment of hip and knee osteoarthritis. J Rheumatol 1992; 19 (1): 130–4.
9. Brater CG. Drug-drug and drug-disease interactions with nonsteroidal anti-inflammatory drugs. Am J Med 1986; 80 (Suppl. 1A): 62–77.
10. Brune K, Graf P. Nonsteroidal anti-inflammatory drugs: influence of extracellular pH on biodistribution and pharmacological effects. Biochemical Pharmacol 1978; 27: 525–30.
11. Chan FK et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347: 2104–10.
12. Collins AJ, Davies J, Dixon A. Aprospective endoscopic study of the effect of Orudis and Oruvail on the upper gastrointestinal tract in patients with osteoarthritis. Br J Rheumatol 1988; 27: 106–9.
13. Dahlen B et al. Celecoxib in patients with asthma and aspirin intolerance. The Celecoxib in Aspirin-Intolerant Asthma Study Group. N Engl J Med 2001; 344: 142.
14. Davies NM. Toxicity of NSAIDs in the large intestine, Dis Colon Rectum 1995; 38 (12): 1311–21.
15. Davies NM, Jamali F. Influence of flurbiprofen dosage form on gastroenteropathy in the rat: evidence of shift in the toxicity site. Pharm Res 1997; 11 (6): 255–9.
16. Davies NM, Skjodt NM. Choosing the Right Nonsteroidal Anti-inflammatory Drug for the Right Patient (A pharmacokinetic Approach). Clin Pharmacokinet 2000; 38 (5): 377–92.
17. Day R, Graham G, Williams K et al. Variability in Response to NSAIDs: Fact or Fiction? Drugs 1988; 36: 631–43.
18. Day RO, Furst DE, Droomgoole SH et al. Relationship of serum naproxen concentration to efficacy in rheumatoid arthritis. Clin Pharm Ther 1982; 31: 733–40.
19. Dwivedi SK, Sattari S, Jamali F et al. Ibuprofen racemate and enantiomers: phase diagram, solubility and thermodynamic studies. Int J Pharm 1992; 87: 95–104.
20. Evans AM. Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs. Clin Pharmacol 1992; 42: 237–56.
21. Fedutes B, Ryba J, Drew G et al. ACR/ARHP Annual Scientific Meeting. November 13–17, 2005. San Diego, CA, 2005. Abstract 628.
22. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351: 1709–11.
23. Fries S, Grosser T, Price TS. Marked Interindividual Variability in the Response to Selective Inhibitors of Cyclooxygenase-2. Gastroenterology 2006; 130: 55–64.
24. Furst D. Are there significant differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salycilate, and nonacetylated nonsteroidal anti-inflammatory drugs. Arthritis Rheum 1994; 37: 1–9.
25. Gall E, Caperton E, McComb J et al. Clinical comparison of ibuprofen, fenoprofen, calcium, naproxen and tolmetin sodium in rheumatoid arthritis. J Rheumatol 1982; 9: 402–7.
26. Goldstein JL et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3: 133–41.
27. Gotzcche P, Hvidberg E, Juul P et al. Rational choice of dose: Insufficient background knowledge? Rational Drug Ther 1986; 20 (7): 1–7.
28. Hinz B, Renner B, Brune K. Drug Insight: Cyclo-Oxygenase-2 Inhibitors–A Critical Appraisal. Nat Clin Pract Rheumatol 2007; 3 (10): 552–60.
29. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional nonsteroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 330: 1366.
30. Hogenesch JB, Panda S, Kay S, Takahashi JS. Circadian transcriptional output in the SCN and liver of the mouse. Novartis Foundation Symposium 2003; 253: 171–183; discussion 52–55; 102–109.
31. Huskisson E, Woolf D, Balme H et al. Four new anti-inflammatory drugs: responses and variations. BMJ 1976; 1: 1048–9.
32. Jalali S, Macfarlane JG, Grace EM et al. Frequency of administration of short half-life nonsteroidal anti-inflammatory analgesics (NSAIDs): studies with ibuprofen. Clin Exp Rheumatol 1986; 4: 91–3.
33. Jamali F. Pharmacokinetics of enantiomers of chiral non-steroidal anti-inflammatory drugs. Eur. J Drug Metab Pharmacokinet 1988; 13: 1–9.
34. Jamali F, Mehvar R, Russell AS et al. Human pharmacokinetics of ibuprofen enantiomers following different doses and formulations: intestinal chiral inversion. J Pharm Sci 1991; 81: 221–5.
35. Kauffman RE, Nelson MV. Effect of age on ibuprofen pharmacokinetics and antipyretic response. J Pediatr 1992; 121: 969–73.
36. Kean WF, Buchanan WW. Variables affecting the absorption of nonsteroidal anti-inflammatory drugs from the gastro-intestinal tract. Jpn J Rheumatol 1987; 1 (3): 159–70.
37. Kearney PM et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302–8.
38. Lai KC et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005; 118: 1271–8.
39. Laine L et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomized comparison. Lancet 2007; 369: 465–73.
40. Lanza FL, Royer GL, Nelson RS. Endoscopic evaluation of theeffects of aspirin, buffered aspirin, and enteric-coated aspirin ongastric and duodenal mucosa. N Engl J Med 1980; 303: 136–8.
41. Lee Yun-Sil, Kim Hyungsuk, Wu Tian-Xia et al. Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs. Clin Pharmacol Ther 2006; 407–18.
42. Maiden L et al. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005; 128: 1172–8.
43. Meffin PJ. The effects of renal dysfunction on the disposition of NSAIDs forming acyl-glucuronides. Agents Actions 1985; 17: 85–9.
44. Pruss T, Gardocki J, Taylor R. Evaluation of the analgesic properties of zomepirac. J Clin Pharmacol 1980; 20: 216–22.
45. Rabausch K et al. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX2-derived prostaglandins. Circ Res 2005; 96: e1–6.
46. Richman AJ, Su EY, Ho G. Reciprocal relationship of synovial fluid volume and oxygen tension. Arthritis Rheum 1981; 24: 701–5.
47. Scott D, Roden S, Marshall J et al. Variation in responses to nonsteroidal anti-inflammatory drugs. Br J Clin Pharmacol 1982; 14: 691–4.
48. Singh G et al. Both selective COX-2 inhibitors and non-selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis: selectivity is with the patient, not the drug class. Ann Rheum Dis 2005; 64 (Suppl. III): 85.
49. Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2005; 108: 47–51.
50. Szczeklik A et al. Safety of a specific COX2 inhibitor in aspirininduced asthma. Clin Exp Allergy 2001; 31: 219–25.
51. Upton RA, Williams RL, Kelly J et al. Naproxen pharmacokinetics in the elderly. Br J Clin Pharmacol 1984; 18: 207–14.
52. Van Den Ouweland FA, Gribnau FWJ, Van Ginneken CAM et al. Naproxen kinetics and disease activity in rheumatoid arthritis: a within-patient study. Clin Pharmacol Ther 1988; 43: 79–85.
53. Verbeeck RK. Pathophysiological factors affecting the pharmacokinetics of nonsteroidal antiinflammatory drugs. J Rheumatol 1988; 15 (Suppl. 17): 44–57.
54. Wasner C, Britton M, Kraines R et al. Nonsteroidal anti-inflammatory agents in rheumatoid arthritis and ankylosing spondylitis. J Am Med Association 1982; 246: 2168–72.
55. Wax J, Clinger A, Varner P et al. Relationship of the enterohepatic cycle to ulcerogenesis in the rat small bowel with flufenamic acid. Gastroenterology 1970; 58 (6): 772–9.
56. Whitcomb DC. Pathophysiology of nonsteroidal anti-inflammatory drug-induced intestinal strictures [letter]. Gastroenterology 1993; 105 (5): 1590.
57. Woessner KM et al. The safety of celecoxib in patients with aspirinsensitive asthma. Arthritis Rheum 2002; 46: 2201–6.
58. Wynne HA, Rawlins MD. Are systemic levels of nonsteroidal antiinflammatory drugs relevant to acute upper gastrointestinal haemorrhage? Eur J Clin Pharmacol 1993; 44: 309–13.